[{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Launch Doptelet\u00ae (Avatrombopag) in Europe","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives European Commission Approval for its Pegfilgrastim Biosimilar Stimufend\u00ae - Fresenius Kabi Global","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend\u00ae (pegfilgrastim-fpgk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Fresenius Kabi AB Brunna"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
U.S.FDA has approved its biosimilar, Stimufend® (pegfilgrastim-fpgk), for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Stimufend (pegfilgrastim) is a long-acting form of filgrastim (recombinant human granulocyte colony-stimulating factor or G-CSF) which serves to stimulate the production of white blood cells (neutrophils).
Doptelet (avatrombopag) is designed to mimic the biologic effects of thrombopoietin in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count, according to Sobi.